Nelova (Ethinylestradiol, Etonogestrel)

The ring releases ethinyloestradiol and etonogestrel, which suppress the release of follicle‑stimulating and luteinizing hormones, thereby inhibiting ovulation. The progestogen also thickens cervical mucus and alters the endometrial lining, creating multiple barriers to fertilisation and implantation.

Nelova is supplied as a pre‑filled vaginal ring that is inserted by the user and left in place for three weeks, followed by a one‑week ring‑free interval. The exact dosing schedule is determined by the prescribing clinician based on individual health factors.

Nelova is contraindicated during pregnancy because it is intended to prevent conception. If pregnancy occurs, the ring should be removed immediately. Use during breastfeeding is generally not recommended without medical advice, as hormonal exposure may affect milk production.

To request Nelova, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nelova delivers hormones via a vaginal ring, offering steady plasma levels and a three‑week wear schedule, unlike daily oral pills that require strict adherence. Compared with transdermal patches, the ring is less visible and may cause fewer skin‑related reactions, while providing comparable contraceptive efficacy.

Nelova should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from direct sunlight, moisture and excessive heat to maintain its integrity throughout its shelf life.

The ring is inserted into the vagina by the user or a healthcare professional and left in place for three consecutive weeks. After a one‑week break, a new ring is inserted to continue contraception. No additional dosing is required during the wear period.

Serious risks include venous thromboembolism, pulmonary embolism, stroke, myocardial infarction, severe allergic reactions, and hepatic disorders. Women with a history of clotting disorders, smoking over age 35, uncontrolled hypertension, or certain liver diseases should avoid using Nelova.

Nelova is contraindicated in women with a known or suspected pregnancy, active or past thromboembolic disease, uncontrolled hypertension, severe liver disease, breast cancer, or in smokers over 35 years of age. It should also be avoided in individuals with known hypersensitivity to any component of the ring.